N- terminal pro brain natriuratic peptide (nt-probnp) in apparently healthy subjects compared to metabolic syndrome subjects

Abstract

Background and objectives: B –type natriuretic peptide is synthesized in myocardial cells to respond to increased wall stress in association with heart failure or acute myocardial ischemia. High B –type natriuretic peptide and high Nt-pro B –type natriuretic peptide levels are candidates for cardiovascular risk markers and hypertension, left ventricular hypertrophy, and albuminuria. The level and relation of Nt-pro B –type natriuretic peptide with metabolic syndrome was examined in this study. Methods: In this case-control investigation, level of Nt-pro B –type natriuretic peptide of 80 metabolic syndrome patients diagnosed based on the International Diabetes Federation guidelines was compared to its level in 40 healthy controls. The subjects who accompanied the diabetic patients at Duhok Diabetes Center were screened for inclusion and exclusion criteria between the first March and May 2019. Results: The concentrations of triglyceride (215.09 vs. 104.02 mg/dL), total cholesterol (179.68 vs. 162.75mg/dL), and fasting blood glucose (188.71 vs. 88.08 mg/dL) were significantly higher in metabolic syndrome patients compared to the healthy controls, respectively. Nt-pro B –type natriuretic peptide was significantly lower in patients in contrast with healthy individuals (35.00 vs. 46.00 pg/mL), respectively. However, the proBNP level was not significantly different in metabolic syndrome patients with normal and abnormal biochemical parameters. Conclusions: This study showed a significantly lower concentration of Nt-proBNP in metabolic syndrome compared to healthy controls. However, the study did not find a significant correlation with content of metabolic syndrome.